Blog

Vivek Subbiah

Dec 20, 2024, 17:31

Vivek Subbiah: Thrilled to Share My Latest Blog with AACR

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:

” Thrilled to Share My Latest Blog with AACR American Association for Cancer Research.

2024 was a terrific year for precision oncology and looking forward for more advances in 2025.

So excited to announce that I’ve had the incredible opportunity to contribute to the AACR blog, where I explore the thought-provoking topic: Creating a World Where Precision Oncology is a Reality for All.

In this piece, the AACR team asked me to explore my personal insights and vision on how precision oncology, coupled with the power of AI, can revolutionize the future of cancer care.

It’s about thinking globally and acting locally to make precision oncology accessible and effective for everyone.

I’m passionate about the potential of these advancements to transform lives and am eager to share my thoughts.”

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.

More posts featuring Vivek Subbiah.